1210P The preliminary efficacy and safety of KN026 combined with KN046 treatment in HER2-positive locally advanced unresectable or metastatic gastric/gastroesophageal junction cancer without prior systemic treatment in a phase II study

L Shen,J Gong,Z Niu,R Zhao,L Chen L Chen,L Liu L Liu,T Deng,L Lu L Lu,Y Zhang,Z Li Z Li,X Li X Li,B Xia B Xia

doi:10.1016/j.annonc.2022.07.1328

1210P The preliminary efficacy and safety of KN026 combined with KN046 treatment in HER2-positive locally advanced unresectable or metastatic gastric/gastroesophageal junction cancer without prior systemic treatment in a phase II study

L Shen, J Gong + Show 10 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.1328

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2022
Citations: 7	License type: publisher-specific-oa

Affiliation: Peking University Cancer Hospital, Shandong Tumor Hospital, First Affiliated Hospital of Xiamen University, Tianjin Medical University Cancer Institute and Hospital

#Bispecific Antibody #Prior Systemic Treatment + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

KN026 is a novel bispecific antibody that simultaneously binds to two distinct HER2 epitopes. KN046 is a novel bispecific antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86. An IIT study (KN046-IST-02) had proved efficacy and safety of KN026 combined with KN046 for late line HER2 positive gastrointestinal cancer.

Full Text